Telectronics Pty Ltd was an Australian company best known for its role in developing the pacemaker. It was located in Lane Cove, Sydney. In 1988 the business was acquired by Pacific Dunlop. [1] However, legal claims resulting from the sale of faulty pacemaker electrode leads inherited by the company in acquisition of Cordis Corporation of Miami led to eventual sale of the assets of the company and Pacific Dunlop restructuring itself into Ansell.
Telectronics Pty Limited was incorporated in Sydney, Australia, in 1963 [1] [2] [3] by technician and initial financier Noel Gray and engineer Geoffrey Wickham initially designing and manufacturing industrial and scientific instruments but diversifying into medical electronics and commencing cardiac pacemaker research in 1964. [4] [5] The corporate name was derived from "Television and Electronic Services", operated by Noel Gray as a sole trader from 1959 to 1964. [3]
The company made significant contributions to pacemaker technology including the first definition of the relationship between surface area of the heart electrodes & pacing pulse characteristics, the first use of integrated circuits and the first hermetic titanium encapsulation. [2]
The company's first model, designated P1, was implanted in three volunteer terminally ill patients in December '64 - January'65, [2] while 2 control samples were retained in a 37 °C. saline bath. This initial design used PNP - NPN electronics to deliver a 2.0 millisecond pulse to the Jeffcoat epicardial electrodes, and was powered by 4 Mallory mercuric oxide-zinc cells (mercury battery), all encapsulated in epoxy resin with a final dip coat of a mix of epoxy and titanium dioxide. All 3 implants failed in ability to maintain capture of the heart after periods of up to 35 weeks. These failures were later proven to be due to the excessively large surface area of the electrodes.
The initial clinical experience led to further animal research using mongrel dogs at the laboratories of the University of Sydney medical school and at the Royal North Shore Hospital's Wellcome laboratory. In this research measurements were made of electrode impedance and pacing threshold energy over a range of pulse voltages and pulse widths, using intramyocardial electrodes of 10, 20 & 50 square millimeters surface area. The chronic measurements allowed plotting of the relationship between electrode surface area and pulse voltage/width, leading to a conclusion that an electrode area between 10 & 30 mm2 was optimum in terms of energy needed when combined with a pulse width of only 0.5 milliseconds.
These characteristics were incorporated in the next design to be implanted in humans, the model P4, which employed 30 mm2 area intramyocardial electrodes (and later transvenous pacing electrodes), a very conservative 7.5 volt pulse and for further conservatism a magnetically operated switch which could be actuated from outside the body to change the pulse width from 0.5 to 1.0 millisecond.
The 0.5 millisecond pulse width became the standard for later Telectronics models and became the approximate standard for all pacemaker manufacturers by the late 70's, [3] until the evolution of externally programmable/monitorable pacemakers using digital electronics in the late 1980s.
Research also included dissection and analysis of the failure modes of explanted pacemakers of any manufacturer. Most failures were due to an internal short circuit of one of the cells of the multicell battery due to the growth of metallic dendrites; or the result of water vapour diffusing though the epoxy resin encapsulation. [6] The only suitable cell available at the time was the mercuric oxide-zinc cell, so the battery problems remained. In 1967 Telectronics commenced research into the technologies which could allow hermetic sealing of the pacemaker to preclude water vapour penetration and, as an interim measure contracted AWM a subsidiary of Amalgamated Wireless Australia Limited (AWA) to develop integrated circuits for the electronics. These early integrated circuits were developed by David R Money who later joined Telectronics and later still led development of the cochlear implant for the profoundly deaf. [7] The circuits were analogue type, housed in hermetically sealed ceramic military 'flat packs' with redundant double gold bonding of the terminations. The IC's were first used in the model P7 of 1969. [2]
The first hermetically sealed models were the P8-9-10 of 1971 [8] using titanium encapsulation with ceramic terminal insulation, developed by David J Cowdery. Bonding of the ceramic was performed using vacuum brazing and an alloy of titanium/nickel with a small percentage of copper. The final hermetic sealing of the titanium capsule was performed by a TIG argon welding process within a large bell jar on an automated analogue controlled machine designed and built by Cowdery. These were the first pacemakers using the conventional battery to be hermetically sealed. Gas products of the battery were absorbed by a chemical 'getter'. Some examples of these models survived to beyond 5 years. [2] By the late 80's TIG welding was replaced by laser welding.
In 1971 Telectronics commenced testing samples of a new type of energy source for pacemakers, the lithium cell (lithium battery) being developed by Wilson Greatbatch and in 1972 commenced development of a range of integrated circuits capable of operation from the 2.8 volts of the cell while providing a stimulating pulse of 4.5 volts. The combined technologies of a lithium cell, integrated circuits, hermetic titanium casing and an 0.5 millisecond pulse was first used clinically in 1974 in the model 120 pacemaker which was state of the art for that time. In 1981 a study of 28,669 Telectronics lithium powered implants showed a cumulative survival of 99.88% and a MTTF of 12,260 months. [9] The longest surviving model 120 was electively explanted in 1993 after 17 years of operation.
Control of Telectronics was gained in 1967 by Nucleus Holdings. [4] Telectronics Inc. was incorporated in the US in 1974, and in 1977 commenced US manufacture from the former General Electric facility in Milwaukee, later relocating to Denver. A manufacturing plant was also established at Châtellerault France, in 1978.
In 1988 Nucleus Limited was acquired by Pacific Dunlop. At that time Nucleus Limited contained offshoots such as Telectronics, Medtel, Ausonics, Domedica and Cochlear Pty Ltd. Cochlear Limited which developed the cochlear implant was floated on the Australian stock market. Pacific Dunlop was hoping to diversify away from so-called rustbelt companies. At the time of acquisition, Telectronics was number 2 in the worldwide pacemaker market. [10] [11] [12]
In January 1995, Telectronics was forced to recall thousands of model 801 atrial "J" leads by the Food and Drug Administration leading to the company having to eventually settle legal claims at a cost of hundreds of millions of dollars. [13] The cause of the recall was a "J lead" electrode, utilizing a rigid stylet within the helix of the electrode lead, inherited by the company in acquisition of pacemaker lead manufacturer Cordis Corporation of Miami. The inherent dangers arising from incorporation of a rigid stylet had been demonstrated by Telectronics, Sydney, in 1967. In 1996 Pacific Dunlop sold most of the assets of Telectronics Limited to St Jude Medical of Minnesota [14] and Telectronics Pty Limited is now a shelf company TPLC Pty. Ltd. [15] Pacific Dunlop restructured in 2001 becoming Ansell with the high cost of the Telectronics settlement being a contributing factor in the decision.[ citation needed ]
An artificial cardiac pacemaker or just pacemaker is a medical device that generates electrical impulses delivered by electrodes to the chambers of the heart either the upper atria, or lower ventricles to cause the targeted chambers to contract and pump blood. By doing so, the pacemaker regulates the function of the electrical conduction system of the heart.
A lithium-ion battery or Li-ion battery is a type of rechargeable battery composed of cells in which lithium ions move from the negative electrode through an electrolyte to the positive electrode during discharge and back when charging. Li-ion cells use an intercalated lithium compound as the material at the positive electrode and typically graphite at the negative electrode. Li-ion batteries have a high energy density, no memory effect and low self-discharge. Cells can be manufactured to prioritize either energy or power density. They can however be a safety hazard since they contain flammable electrolytes and if damaged or incorrectly charged can lead to explosions and fires.
Wilson Greatbatch was an American engineer and pioneering inventor. He held more than 325 patents and was a member of the National Inventors Hall of Fame and a recipient of the Lemelson–MIT Prize and the National Medal of Technology and Innovation (1990).
The AA battery is a standard size single cell cylindrical dry battery. The IEC 60086 system calls the size R6, and ANSI C18 calls it 15. It is named UM-3 by JIS of Japan. Historically, it is known as D14 or HP7 in official documentation in the United Kingdom, or a pen cell.
An implant is a medical device manufactured to replace a missing biological structure, support a damaged biological structure, or enhance an existing biological structure. Medical implants are man-made devices, in contrast to a transplant, which is a transplanted biomedical tissue. The surface of implants that contact the body might be made of a biomedical material such as titanium, silicone, or apatite depending on what is the most functional. In some cases implants contain electronics, e.g. artificial pacemaker and cochlear implants. Some implants are bioactive, such as subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents.
Neuroprosthetics is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses. They are sometimes contrasted with a brain–computer interface, which connects the brain to a computer rather than a device meant to replace missing biological functionality.
Geoffrey Gordon Wickham is one of the pioneers of cardiac pacemaking.
[[File:Portrait of Professor Graeme Clarkwg macaroni Wegner.png|thumb|Portrait of Professor Graeme Clark Oil on Canvas 2000 Peter Wegner National Portrait Gallery Australia|300px]] Graeme Milbourne Clark AC is an Australian Professor of Otolaryngology at the University of Melbourne. His work in ENT surgery, electronics and speech science contributed towards the development of the multiple-channel cochlear implant. His invention was later produced and sold by Cochlear Limited.
Noel Desmond Gray Senior design engineer at the Philips subsidiary Kriesler and medical student at the University of Sydney after War service in the Royal Australian Electrical and Mechanical Engineers. He formed the desire to start the Medical Device Industry at Med School and co-founded Telectronics Pty Ltd.
Nucleus Limited began as a private company in Sydney, Australia, in 1965. It was founded by former Watson-Victor executive Paul Murray Trainor, after acquisition of X-ray sales & service company Scientific & General.
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Anthony J. Adducci was a pioneer of the medical device industry in Minnesota. He is best known for co-founding Cardiac Pacemakers, Inc., the company that manufactured the world's first lithium battery powered artificial pacemaker. The lithium-iodide cell revolutionized the medical industry and is now the standard cell for pacemakers.
A nickel–hydrogen battery (NiH2 or Ni–H2) is a rechargeable electrochemical power source based on nickel and hydrogen. It differs from a nickel–metal hydride (NiMH) battery by the use of hydrogen in gaseous form, stored in a pressurized cell at up to 1200 psi (82.7 bar) pressure. The nickel–hydrogen battery was patented on February 25, 1971 by Alexandr Ilich Kloss and Boris Ioselevich Tsenter in the United States.
The thin film lithium-ion battery is a form of solid-state battery. Its development is motivated by the prospect of combining the advantages of solid-state batteries with the advantages of thin-film manufacturing processes.
Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.
Pacific Dunlop was a highly diversified Australian conglomerate company that operated in, among other things, the Automotive, textile, electronics and biotechnology industries. Products commercialised included tires, car batteries, cables, clothing, electronics, bedding, condoms.
A High capacity oceanographic lithium battery pack is a type of battery pack used by oceanographers. Physical Oceanographers use high capacity lithium battery packs for long term deployments to extend the duration of the deployments and gather more data. Oceanographers often work in far away sites that are difficult to get to. The cost of getting to these remote sites, often by ship, can dominate the cost of an investigation. This motivates oceanographers to extend the duration of their deployments so that they can visit them less often. This means, among other things, increasing the capacity of their battery packs.
Implant failure refers to the failure of any medical implant to meet the claims of its manufacturer or the health care provider involved in its installation. Implant failure can have any number of causes. The rates of failure vary for different implants.
Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It sold microprocessor-controlled insulin pumps and equipment to regulate heart rhythm. It developed therapies to treat irregular heartbeat. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. is a subsidiary of Boston Scientific Corporation.
The David Dewhurst award is a bronze medal bestowed by Engineers Australia and is the most distinguished accolade within their biomedical engineering discipline. It is named in honour of David John Dewhurst, an outstanding Australian biophysicist and biomedical engineer who performed pioneering work in the area of the cochlear implant. The award was inaugurated in 1994 as the Eminent Biomedical Engineers Award and its first winner was David Dewhurst. Following his death in 1996 the award’s name was changed to the David Dewhurst Award as a permanent memorial.